PMID: 2511114Sep 1, 1989Paper

A 4-day chemosensitivity assay in vitro reliably predicts clinical response of patients with acute leukemia

Haematologica
A M BarziM Schippa

Abstract

To assess the individual chemosensitivity of human acute leukemias to anticancer agents, a rapid in vitro assay based on 125[I]-5-iodo-2'-deoxyuridine (125IUdR) incorporation into the DNA of neoplastic cells was tested. It was found that: a) the assay reflects the higher in vivo responsiveness of acute lymphoid leukemias with respect to acute non-lymphoid leukemias; b) samples from responder patients were more sensitive in vitro to antileukemic agents than were samples from non-responder patients; c) the assay in this study had an 86% accuracy in predicting response and a 90% accuracy in predicting resistance.

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.